Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Atlas Pipeline Partners, L.P. (APL): An Early Earnings Look

Earnings season is in full swing, with huge numbers of companies having already given their latest quarterly numbers to investors, and Atlas Pipeline Partners, L.P. (NYSE:APL) is stepping up to the plate Monday. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed, knee-jerk decision.

Atlas Pipeline Partners, L.P. (NYSE:APL)

The midstream energy industry has become a vital deliverer of newly found oil and gas to where consumers can make best use of them. Atlas Pipeline Partners isn’t the biggest player in the industry, but it’s trying to take advantage of the opportunity in energy infrastructure. Let’s take an early look at what’s been happening with Atlas Pipeline Partners over the past quarter and what we’re likely to see in its quarterly report next Monday.

Stats on Atlas Pipeline Partners

Analyst EPS Estimate $0.21
Year-Ago EPS ($0.15)
Revenue Estimate $353 million
Change From Year-Ago Revenue 11.8%
Earnings Beats in Past 4 Quarters 0

Source: Yahoo! Finance.

Will Atlas Pipeline Partners finally hit a gusher?
Analysts have become increasingly pessimistic in their assessment of Atlas Pipeline’s earnings over the past few months. They’ve reduced consensus earnings-per-share estimates by nearly a dime, even though that hasn’t stopped the master limited partnership’s units from rising nearly 10% since mid-November.

Atlas was among the big losers in the midstream space in 2012 as it suffered from weak pricing, especially for natural-gas liquids. The MLP has taken steps to remedy its pricing risk, though, hedging its dry-gas and gas-liquids exposure through 2015. That’s a positive step if gas prices remain low, although it reduces the potential upside if natural gas recovers within the next few years.

But during the quarter, Atlas joined the wave of consolidation that has started to pick up in the industry, buying privately held Cardinal Midstream for $600 million. Industry giant Kinder Morgan Inc (NYSE:KMI) has demonstrated the value of using acquisitions to build pipeline networks, as its purchases of El Paso and its affiliated El Paso Pipeline Partners, L.P. (NYSE:EPB) in 2011 and its recently announced bid for Copano Energy, L.L.C. (NASDAQ:CPNO) show how economies of scale can help even the biggest players in the space. Given the huge need for pipeline capacity increases in light of the big ramp-up in production, Atlas has the same kind of potential that El Paso had and that Copano has for major players wanting to boost their midstream holdings.

In the coming report, look for Atlas to discuss its recent tender offer to buy out some of its existing debt. With the company replacing notes due in 2018 with cheaper debt that extends out to 2023, Atlas will reduce its borrowing costs, putting it in even better position to grow — and looking even more attractive to a potential acquirer.

The article Atlas Pipeline Partners: An Early Earnings Look originally appeared on and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends El Paso Pipeline Partners and Kinder Morgan. The Motley Fool owns shares of Kinder Morgan.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!